-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, SUN7tQaiSCfFmsKRV2a91yI8VDwRf/RN4Pi56APfs2QqUKhxKsuzPJe1wbdhSAuE xh8gvqsuTzsJN2ZsJgxauw== 0000914317-03-003623.txt : 20031203 0000914317-03-003623.hdr.sgml : 20031203 20031203140725 ACCESSION NUMBER: 0000914317-03-003623 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20031203 ITEM INFORMATION: Other events FILED AS OF DATE: 20031203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDISCIENCE TECHNOLOGY CORP CENTRAL INDEX KEY: 0000064647 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 221937826 STATE OF INCORPORATION: NJ FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-07405 FILM NUMBER: 031034918 BUSINESS ADDRESS: STREET 1: 1235 FOLKESTONE WY CITY: CHERRY HILL STATE: NJ ZIP: 08034 BUSINESS PHONE: 6094287952 MAIL ADDRESS: STREET 1: 1235 FOLKESTONE WAY CITY: CHERRY HILL STATE: NJ ZIP: 08034 FORMER COMPANY: FORMER CONFORMED NAME: CARDIAC TECHNIQUES INC DATE OF NAME CHANGE: 19730920 8-K 1 form8k-55863_mediscience.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON DC 20549 CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 MEDISCIENCE TECHNOLOGY CORPORATION (EXACT NAME OF REGISTRANT AS SPECIFIED ON CHARTER) NEW JERSEY 0-7405 22-1937826 - -------------------------------------------------------------------------------- (State of Incorporation) (IRS Employer (Commission File No.) Identification No.) 1235 Folkestone Way, P.O. Box 598, Cherry Hill, New Jersey 08003 - -------------------------------------------------------------------------------- Registrant's telephone number. Including area code (856) 428 7952 - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- (Former Address, if changed, since last report) Item 5. Other Materially Important Events (Submitted in full compliance with sections 8-K 1.01 and 2.01 re: "materiality" as applicable and in fulfillment of SEC Section 6, 6.01 Regulation (FD) Full Disclosure, and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. Cherry Hill, NJ ( Dec. 3, 2003)--Registrant, reports herein the contractual acquisition of two exclusive and "material" world-wide licenses for US patent applications recently filed by The Research Foundation City University of New York (RFCUNY). 1. "Stokes-Shift Fluorescence Spectroscopy for Detection of Disease and Physiological State of Specimen" and 2. "Three-Dimensional Radiative Transfer Tomography for Turbid Media." The patents, when issued, would extend and continue the Company's core technology for an additional 17+ years, thus maintaining Registrants "Intellectual Property" leadership in the Optical Biopsy field. SEC Section 6, 6.01 Regulation (FD) Full Disclosure (IEEE Journal of Selected Topics in Quantum Electronics March-April 2003 Vol. 9, Dr. R.R. Alfano et al pages 148 and page 189.incorporated herein by reference. Registrant Press Release dtd: Dec. 3, 2003 attached and a part hereof (Exhibit "A") and placed on Registrants Web Page: MEDISCIENCETECH.com SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized MEDICSCIENCE TECHNOLOGY CORPORATION /S/ Peter Katevatis ----------------------------------- Peter Katevatis, Chairman Dated December 3, 2003 For Immediate Release Contact (MTC) (201) 818 0050 Pres. COO Michael Engelhart EXHIBIT "A" mengelhart@thmgroup.com - ----------- ----------------------- MEDISCIENCE TECHNOLOGY CORP. (OTC-MDSC) SECURES EXCLUSIVE WORLD-WIDE LICENSE TO US molecular imaging PATENT APPLICATIONS, EXPECTED TO EXTEND CORE TECHNOLOGY ADDITIONAL 17+ YEARS, Cherry Hill, NJ (Dec. 3, 2003)--Mediscience Technology Corp. (MTC), (OTCBB- "MDSC") of Cherry Hill New Jersey, a developer of imaging technology for molecular detection of cancer and physiological change, announced its contractual acquisition of two exclusive world-wide licenses for US patent applications filed by The Research Foundation City University of New York (RFCUNY). 1. "Stokes-Shift Fluorescence spectroscopy for detection of disease and physiological state of specimen" and 2. "Three-dimensional Radiative Transfer Tomography for Turbid Media." The work results from the Company's continual 10-year+ University research funding relationship. President and Chief Operating Officer Michael Engelhart and the inventor Dr. Robert Alfano state that "the patents, when issued, would extend the Company's core technology in Optical Biopsy for an additional 17+ years, thus expanding, maintaining and continuing our IP leadership in the Optical Biopsy field". NOTE: SEE: Mediscience SEC/EDGAR 8-k filing dated: December 4, 2003 Web Page: MEDISCIENCETECH.com See (IEEE Journal of selected topics in Quantum Electronics March-April 2003 Vol. 9 Dr. Alfano page 148 and page 189. INVESTOR NOTICE: ---------------- Certain of the matters discussed in this announcement contain forward-looking statements that involve material risks to and uncertainties in the company's business that may cause actual results to differ materially from those anticipated by the statements made herein. Such risks and uncertainties include among other things, the availability of financing, the company's ability to implement its long-range business plan for various applications of its technology; the company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary US regulatory clearances applicable to applications of the company' technology; and management of growth and other risked and uncertainties that may be detailed from time to time in the company's reports filed with the Securities and Exchange Commission. This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD, disclosure and Section 7 and 7.0 as well as all applicable and presently effective Sarbanes-Oxley disclosure requirements under Regulation G. Contact Persons: Pres. COO Michael Engelhart (201) 818 0050 mengelhart@thmgroup.com: Mediscience Technology Corp. Peter Katevatis Esq. Chairman/CEO metpk@aol.com. -----END PRIVACY-ENHANCED MESSAGE-----